NAC Meeting Edmonton April 2016

Slides:

Advertisements

Similar presentations

Coagulopathy and blood component transfusion in trauma

Advertisements

Part 2 Terry Kotrla, MS, MT(ASCP)BB

University of Minnesota – School of Nursing Spring Research Day Glycemic Control of Critically Ill Patients Lynn Jensen, RN; Jessica Swearingen, BCPS,

Vanderbilt Pediatric Hematology Anticoagulation Guidance Protocol Robert F. Sidonio, Jr. MD, MSc. 4/11/12 Enoxaparin Dosing Goal anti-Xa levels are 0.6.

Massive transfusion: New Protocol

Transfusion Management of massive haemorrhage in children Ongoing severe bleeding (overt / covert) and received 20ml/kg of red cells or 40ml/kg of any.

Blood Components Dosage And Their Administration

Faculty of Allied Medical Science

A/Prof Larry McNicol. Improves the patient’s own blood and avoids unnecessary transfusions. ‘THE THREE PILLARS’ Minimise blood loss Optimise blood volume.

BLOOD BANKING 1- BLOOD PRODUCTS 2- AUTOLOGOUS TRANSFUSION M. H. Shaheen Maadi Armed Forces Hospital.

Massive Transfusion Mary Jo Drew, MD, MHSA Chief Medical Officer Pacific Northwest Blood Services Region.

Transfusion Quiz “Their Lives in Your Hands” Doctors.

Definition of Massive Transfusion Replacement of a blood volume equivalent within 24hr Transfusion>10 unit within 24 hr Transfusion > 4 units in 1 hr.

MTP Octaplex rFVIIa Calgary. Massive Transfusion Protocol.

1 Dosage Calculation Review Review based on required readings selected from: Pickar, G. (2007). Dosage calculation: A ratio-proportion approach (2nd ed.).

Rituximab (RITUXAN) & Multiple Sclerosis

4th year medical students Blood Component Therapy Salwa I Hindawi MSc FRCPath CTM Director of Blood Transfusion Services KAUH. Jeddah.

Kcentra In-service Adam M. Spaulding, PharmD, BCPS

1 Randomization as a Concept to Improve Follow-Up and Reduce Cost in Long-Term Health Related Quality of Life Studies Addressing Cardiac Surgery Scott.

10 Rights of Medication Administration

Senior clinician Request: a o 4 units RBC o 2 units FFP Consider: a o 1 adult therapeutic dose platelets o tranexamic acid in trauma patients Include:

CRYOPRECIPITATE USE IN 25 CANADIAN HOSPITALS: COMMONLY USED OUTSIDE OF THE PUBLISHED GUIDELINES Edward C Alport, Jeannie L Callum, Susan Nahirniak, Bernie.

Administering Thrombolysis Early Management

Transfusion Management of Massive Haemorrhage in Adults Patient bleeding / collapses Ongoing severe bleeding eg: 150 mls/min and Clinical shock Administer.

Preventing Surgical Infections Through Effective Perioperative Antibiotic Administration Project Team Members: Anesthesia Infectious Disease Pharmacy Surgical.

The Massive Transfusion Protocol An Aide Memoire 1.

Good Morning 6 June Uremic Bleeding: Pathogenesis and Therapy 麻醉科林子富.

Preparation of blood components

Platelet Transfusions Indications, dose and administration

{ Challenging Case Presentations From South Texas Methodist Hospital REGIONAL SYSTEMS OF CARE DEMONSTRATION PROJECT: MISSION: LIFELINE™ STEMI SYSTEMS ACCELERATOR.

Patient Blood Management Guidelines: Module 6 Neonatal and Paediatrics Roles Senior clinician Coordinate team and allocate roles Determine volume and type.

Sublingual Allergy Treatment. Sublingual Immunotherapy Immunotherapy is widely used by allergy specialists because it treats the underlying cause of allergic.

Transfusion Christine Sullivan Transfusion Practitioner.

Management Control or elimination of the underlying cause Severe DIC: – Control of hemodynamic parameters – Respiratory support – Surgery Attempts to treat.

The Effects of Intravenous Acetaminophen Use on Robot-Assisted Pelvic Surgery Patients Nichole Witmyer, Pharm.D. St. Dominic Hospital Jackson, Mississippi.

Systemic anticoagulation during ECMO is intended to control thrombin generation and limit the risk for thrombotic and hemorrhagic complications.

Human Serum Albumin (DB00062) Approved Drug

K A U H Blood bank Wesaam Al-Sheyyab.

Damian Gimpel Waikato Cardiothoracic Unit Journal Club

Dr Mohamed Ouda MRCGP 1-Reason for choice of audit 3-Standards set

GTP Scenario # 4 September 17,2005.

Warfarin Toxicity Treatment & Management

Duration of Therapy of Colony Stimulating Factors in Oncology

Medication In-Service:

Laura Cooling MD, MS Associate Medical Director Transfusion Medicine

NAC meeting November 6-7, 2014.

A Quality Improvement Project

Alberta Health Services

SUPPORTING THE RUN Blood Transfusion Services Role in Assisting with Patient Care during Massive Transfusion Events.

M. Taher Shabani-Rad Susan Nahirniak NAC Meeting Nov Toronto

NAC meeting April 30-May 1, 2014.

Reversal of Direct Oral Anticoagulants (DOAC)

NAC National Advisory Committee Canadian Blood Services Review of Select Distribution Trends April 25, 2013 Toronto Rick Trifunov Director, Plasma.

Nova Scotia Update NAC Meeting October 15-16, 2015.

PT CBS BLC Updates NAC Face to Face Bernadette Muise

CBS Transfusable Products Update

Brian Muirhead FRCPC Assistant Professor, University of Manitoba

NAC Meeting April Calgary

Introduction to Transfusion: Ordering Blood Products

Project Team: Anesthesia Infectious Disease Pharmacy Surgical Services

M Ranucci, E Baryshnikova British Journal of Anaesthesia

Fibrinogen concentrate reduces intraoperative bleeding when used as first-line hemostatic therapy during major aortic replacement surgery: Results from.

Roberta Rossini et al. JCIN 2018;11:

The Basics of Intravenous Fluid Administration

Introduction to Research Methods in Psychology

Use of recombinant factor VIIa as a rescue treatment for intractable bleeding following repeat aortic arch repair Greg Stratmann, MD, PhD, Isobel A Russell,

Blood Components Dosage And Their Administration

Variability of plasma aprotinin concentrations in pediatric patients undergoing cardiac surgery William C Oliver, MD, David N Fass, PhD, Gregory A Nuttall,

Parenteral Dosages Chapter 12

Presentation transcript:

NAC Meeting Edmonton April 2016 The Efficacy and Cost-effectiveness of Fibrinogen Concentrate Compared With Cryoprecipitate in Major Bleeding Patients NAC Meeting Edmonton April 2016

Non-cardiac patients would receive a low dose FC (1.0-2.0 gr) dose. The Efficacy and Cost-effectiveness of Fibrinogen Concentrate Compared With Cryoprecipitate in Major Bleeding Patients (1) Patients for the study would be identified by having a cryoprecipitate order placed for infusion. The TM physician would then contact the attending physician and ask if they would be willing to switch to fibrinogen concentrate instead. Fibrinogen concentrate would then be administered in the following doses: Cardiovascular patients would receive a 2.0-4.0 gr of fibrinogen following the current recommendation. Non-cardiac patients would receive a low dose FC (1.0-2.0 gr) dose.

The Efficacy and Cost-effectiveness of Fibrinogen Concentrate Compared With Cryoprecipitate in Major Bleeding Patients (2) A total of 120 patients will be selected for the study (60 fibrinogen and 60 cryo). Cryo recipients may be selected from patient who had been already transfused and relevant timely lab data is available for those patients. A chart review would be conducted of approximately 60 patients that received or will receive Cryoprecipitate in 2014/15/16 and of approximately 60 patients that will received fibrinogen concentrate in 2015/16. The data would be analyzed in 2 separate groups: cardiovascular patients and non-cardiovascular patients based on the different dosing schedules. Non-cardiovascular patients may be analyzed in two subgroups of Massively bleeding/non-Massively bleeding (<6 RCs)

The Efficacy and Cost-effectiveness of Fibrinogen Concentrate (Dosing Schedule) FIBRINOGEN Concentrate (RiaSTAP) Each vial of RiaSTAP contains 1.0 gram of Fibrinogen concentrate and increases the fibrinogen levels by 0.5 g/L which is equal to increments achieved by a pool of 10 cryoprecipitate. Dosage suggestions: 1 vials of RiaSTAP (1 grams) when the fibrinogen level is 0.5-1.0 g/L (non-Massively bleeding; mild bleeding, mucosal bleeding etc..). 2 vials of RiaSTAP (2 grams) when the fibrinogen level is <1.0 g/L (Massively Bleeding pts). 1 vial of RiaSTAP when the patient’s Fibrinogen level is between 1.0-1.49 g/L and there is a significant drop in Fibrinogen within the last 6 hours. For STAT cases with coagulopathic bleeding and fibrinogen levels are not available, approve the first vial (1 gram) but the second vial will not be released until the fibrinogen levels are tested (these levels should be collected to be tested before the administration of the first dose of RiaStap). Cardiac surgery – up to 4g per dose is acceptable.

Fibrinogen Result Greater than 1.5 gr/L 1.0 – 1.49 gr/L and a significant drop in Fibrinogen levels in last 6 hours 0.5 - 1.0 gr/L Less than 0.5 gr/L RiaSTAP® Dosing No vials 1 gram (1 vial) 1 gram (1 vial) Non-MB 2 gram (1 vial) Massive Bleeding First vial may be released if Repeat Fibrinogen level is not available. Release of 2nd vial requires Fibrinogen level and TM physician approval. (2 grams is a total maximum dose). 2 grams (2 vials) Release of first 2 vials without fibrinogen level is approved for Cardiac or Vascular surgery patients. Additional vials require Fibrinogen level and TM physician approval.